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Abstract
Purpose Human thyroid development is a complex and still
unexplained process. Thyroid hemiagenesis is a congenital
anomaly, where one of the thyroid lobes fails to develop. In
the majority of patients with thyroid hemiagenesis, the
genetic background remains unknown. The aim of the study
was to search for novel genetic contributors to the etiology
of thyroid hemiagenesis.
Methods A cohort of 34 sporadic patients diagnosed with
thyroid hemiagenesis and one three-generation family were
subjected to comprehensive genomic examination. Initially,
targeted screening of associated transcription factors,
known to be linked to thyroid development, was performed.
As a next step, genomic examinations were applied using
high-resolution microarrays, whereas for the thyroid hemi-
agenesis family, additionally the whole exome sequencing
was performed.
Results Screening of transcription factors revealed no cau-
sative mutations in the studied cohort. Genomic examina-
tions revealed the presence of four recurrent defects (three
deletions and one duplication) affecting highly conservative
proteasome genes PSMA1, PSMA3, and PSMD3. In a
thyroid hemiagenesis family a splice site mutation in a
proteasome gene PSMD2 (c.612T >C cDNA.1170T >C,
g.3271T>C) was found in both affected mother and
daughter.
Conclusions Our results shed a new light on etiology of
thyroid hemiagenesis, so far suspected to be linked only to
mutations in the genes directly involved in the thyroid
development. We demonstrated, for the ﬁrst time, that
genomic alterations in proteasome-associated genes co-
occur in patients presenting this developmental anomaly.
Keywords Thyroid hemiagenesis ● Microarray ● Exome
sequencing ● Thyroid transcription factors ● Proteasome
Introduction
Thyroid hemiagenesis (THA) is a rare congenital anomaly
occurring when one of the thyroid lobes fails to develop.
Bartlomiej Budny and Ewelina Szczepanek-Parulska have contributed
equally to this work.
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The incidence of the disorder is estimated at 0.05–0.5% of the
general population. THA occurs usually as an isolated feature,
more frequently in women than in men [1]. THA belongs to
the broad and heterogeneous spectrum of thyroid dysgenesis,
but in contrast to the other more severe forms, clinical con-
sequences of abnormality rarely include congenital hypo-
thyroidism [2]. The accurate etiology of THA remains
unknown, even though the abnormality was found to be an
inherited condition in a few families, signifying its genetic
origin [3]. Additionally, THA family members commonly
present other thyroid developmental anomalies (i.e., thyroid
agenesis, ectopy or thyroglossal duct cyst) [4]. This, in turn,
suggests common genetic background of different thyroid
developmental anomalies, but also contribution of other fac-
tors modulating expressivity and severity of the deﬁnitive
phenotype. The genes known to regulate thyroid embry-
ogenesis (i.e., NKX2-1, FOXE1, PAX8) are rarely altered in
THA patients, and only one THA familial case was reported
to be caused by a heterozygous mutation in PAX8 [5].
Valuable insights into the etiology of the condition provide
genetic syndromes, where THA appears as a part of complex
phenotype. THA is occasionally concomitant with Williams
and DiGeorge syndromes [6]. In both disorders the respon-
sible altered genetic regions are bearing SHH and TBX genes.
Their mutated mouse orthologues were evidenced to cause
THA in an animal model [7]. TBX1 knockout mice presented
normal development of follicular cells, whereas due to dis-
turbed formation of ultimobranchial bodies the gland lacked
C cells [7]. The animal THA model however, does not reﬂect
accurately the human species, because in surgical specimens
obtained from the THA patients the presence of normal C
cells was demonstrated [8]. Human SHH gene is responsible
for severe developmental conditions like holoprosencephaly,
and there are no evidences of SHH allelism, that may lead to
milder phenotype [9]. Other clues coming from THA mouse
knockouts encouraged researchers to pay particular attention
on human homeobox gene family. The Hoxa3 null mice
particularly show diminished number of follicular cells,
hypoplasia or absence of one thyroid lobe which corresponds
to human THA [10]. In the recent study by Kizys et al.
HOXA3, HOXB3, HOXD3, and PITX2 genes were analyzed
in THA, however no causative mutations were found [11].
Lack of success in identiﬁcation of common genetic
mechanism in THA indicate the need to search for other
genetic targets. In this study, we aimed to look for novel
genetic factors that contribute to the development of THA
in a uniquely large cohort of patients.
Patients and methods
The studied group consisted of 34 unrelated patients and
two familial cases, with THA as an inherited condition
transmitted from mother to daughter. The diagnosis of THA
was conﬁrmed by ultrasound examination and scintiscan.
Recruited patients did not present any concomitant con-
genital developmental disorders. DNA of all affected indi-
viduals and ﬁrst-degree relatives in THA family was
obtained from blood samples. A population cohort of 100
individuals originating from the same region of Poland was
used as a control group.
Genetic examinations
Firstly, we analyzed the genes which role in the thyroid
development was documented in previous studies.
Sequencing of PAX8 (NM_003466), TTF1 (NKX2-1,
NM_001079668), TTF2 (FOXE1, NM_004473), HHEX
(NM_002729), SHH (NM_000193), and TBX1
(NM_080647) genes encompassed coding sequences, with
neighboring intronic regions. Microarray analyses was
performed using Illumina Inﬁnium Human OmniExpress-
12v1.0 beadchip (San Diego, USA) and then for selected
samples on Affymetrix CytoScanHD arrays (2,7M, Santa
Clara, USA). For assays, 200–250 ng of genomic DNA was
used. Array scans were managed using Illumina Geno-
meStudio and Affymetrix Chromosome Analysis Suite
(ChAS). Log2 R ratios and B-allele frequencies were used
for copy number variations (CNVs) identiﬁcation in all
samples. Population speciﬁc CNVs were ﬁltered out (con-
trol cohort of 100 healthy individuals were analyzed pre-
viously using CytoScan 750 K arrays and included in
Poznan University of Medical Sciences database) and then
identiﬁed abnormalities were compared with CNVs anno-
tated in the database of genomic variants. Findings were
validated using Real Time qPCR (ΔΔCT method, Life
Technologies). Complete genomic coordinates regarding
THA patients were deposited in ClinVar database (Table 1).
The whole exome analysis was conducted in a three-
generation family, presenting transmission of THA as an
isolated feature (pedigree presented on Supplementary Fig.
2). Four family members were examined (proband and their
ﬁrst-degree relatives). A total of 1 μg of genomic DNA from
subjects was used for the construction of a library with the
TruSeq DNA Sample Preparation Kit (Illumina). Whole
exome enrichment was performed with the use of DNA
library and TruSeq Exome Enrichment Kit (Illumina). For
pathogenicity evaluation, the following features were
applied: (a) gene/transcript annotations (downloaded from
UCSC GenomeBrowser, hg18), (b) known sequence var-
iants from dbSNP (version 132), 1000 Genomes project
(The 1000 Genomes Project Consortium). NGS ﬁndings
were validated using Sanger sequencing. Strategy presented























































































































































































































































































































































































































































































































































































































































































































































































Prediction of mutations impact and protein network
analysis
The identiﬁed mutations were analyzed for their impact on
protein conformation and functionality. The amino acid
changes were examined using Sift [12], and PolyPhen2 [13]
as well as Splice Site mutations using Human Splicing
Finder (HSF3.0) [14], and MutationTaster [15]. CNVs
encompassing genes, were subjected to a search for phe-
notype relevancy using GENECODIS, whereas functional
annotation was conducted with the database for annotation,
visualization, and integrated discovery [16]. P-values and
numerical scores were calculated to rank networks accord-
ing to their degree of relevance in regards to the different
gene lists.
Results
Sequencing of known thyroid transcription factor genes
(PAX8, NKX2-1, FOXE1, and HHEX) and selected targets,
demonstrated in previous studies to contribute to the thyroid
development (TBX1, SHH) did not reveal mutations in THA
patients. This prompted us to look for genomic abnormal-
ities across sporadic patients, as well as one THA family.
The examination using microarrays revealed CNVs (ran-
ging in size from 5 Kb up to 3.2 Mb). We focused parti-
cularly on cytoregions bearing genes emerging 63 unique
deleterious CNVs. Three deletions turned out to be found in
more than one sporadic patient. Analogous investigation
was conducted for duplications and selection of 18 gains in
copy number were established. Within these loci, a total
number of 24 genes were identiﬁed and one duplication was
found in two unrelated patients. In total four recurrent
CNVs (three deletions, one duplication) were detected. We
explored DGV to ﬁnd overlaps with CNVs reported in large
control populations, and we found an ultra-rare variability
for three out of four regions (not present for PSMD3 gene,
where point mutation in THA family was identiﬁed). All
four regions were statistically signiﬁcant and not coin-
cidently enriched comparing to large control populations.
Microarray data are summarized in Table 1. Recurrent
deletions were harboring highly conservative proteasome
genes PSMA1 (NM_002786, two patients), PSMA3
Fig. 1 Proteasome and protein
units shown to be altered in
THA sporadic patients
(microarray studies, encircled in
red) and familial case (WES, an
arrow). The corresponding gene
names as follow: Rpn1—
PSMD2, Rpn3— PSMD3, α6—
PSMA1, α7—PSMA3
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(NM_002788, two patients) and additionally deletion
encompassing PSMD3 gene (NM_002809, found in one
sporadic patient). In the studied group of patients, deletions
of two other proteasome-associated genes VPS13C
(NM_020821, two patients) and RAD23B (NM_002874,
one patient) were detected.
Exome-wide sequencing in a THA family resulted in
identiﬁcation of 93 alterations. One change, was a splice
site mutation in a proteasome gene PSMD2 (c.612 T >C
cDNA.1170 T>C, g.3271 T >C, NM_002808) found in
affected mother and daughter, and regarding microarray
ﬁndings it was particularly interesting. The mutation intro-
duced an exonic splice sequence (silencer motif), knocking
out one PSMD2 allele. Both microarray and whole exome
sequencing (WES) data were concordant and subsequently
indicating haploinsufﬁciency of core proteasome genes
(Fig. 1).
Recurrent abnormalities were found in 7 out of 34
patients (20%), and therefore an attempt was made to
emerge THA pathways, based on functional interactions
between other detected genes/regions. We used all identi-
ﬁed CNVs (63 deleterious, 18 gains), bearing in total 175
known genes. This examination resulted in identiﬁcation of
four signiﬁcant clusters: (a) protein degradation via pro-
teasome, (b) transmembrane transport (solute carriers), (c)
cytoskeleton maintenance (actin related) and (d) transcrip-
tional regulation, respectively (Supplementary Table 1).
Except proteasome-related genes, none of the above genes
altered in more than one patient.
Discussion
The development of thyroid gland in vertebrates is a mul-
tistep complex process. Recently, a comprehensive review
summarizing the contribution of transcription factors in
thyroid embryogenesis and their role in the differentiation
of thyroid follicular cells was published [17]. Mutations of
these genes are associated with broad spectrum of clinical
features i.e., thyroid hypoplasia, ectopy, agenesis or even
syndromal phenotypes characterized by multiple organ
development failure. Although the knowledge of the
mechanisms involved in the thyroid development has been
expanded, in a substantial portion of patients with thyroid
dysgenesis it was not possible to identify causative muta-
tions. This suggests that other unknown genes may con-
tribute to the disorder. The aim of the present study was to
search for genetic abnormalities explaining the origin of
thyroid bilobation failure in humans presenting as an iso-
lated condition.
The transcription factors (TTFs) (PAX8, FOXE1, HHEX
or, NKX2-1) represent different classes of conservative
transcription factors. They show expression across various
tissues, but appear together exclusively in the thyroid. Their
interaction is crucial for proper organogenesis, and single
TTF perturbation is leading to severe dysgenesis [18]. In
order to identify THA genetic background, a cohort THA
patients and a THA family were screened for mutations in
TTFs. This examination failed to ﬁnd any abnormalities in
known thyroid genes in THA patients under study. This
supports previous ﬁndings, that patients with isolated THA
in majority do not present mutations in TTFs [4]. Therefore,
we searched for defects in other genes that would affect
thyroid bud migration, or stabilization of the bilobar thyroid
structure. We identiﬁed recurrent abnormalities affecting
proteasome genes comprising recently an attractive target
for the studies on developmental mechanisms. The major
function of proteasomes in the cell is degradation of ubi-
quitinated proteins. Their functional insufﬁciency leads to
accumulation of undegraded protein aggregates, which may
exert a toxic effect on the cell. Mutations in proteasome
related genes are linked to a broad spectrum of phenotypes
encompassing neurological, autoimmune, and develop-
mental disorders [19–21]. We found recurrent deletions of
proteasome genes, accounting for portion of patients, that
nevertheless is unlikely coincidental. All of the genes—
PSMA1, PSMA3 and PSMD3 as well as PSMD2 gene in
familial case present haploinsufﬁciency. None of those
genes has been linked to the human disease so far. The
detected c.612T>C mutation in a PSMD2 gene, which is
transmitted together with a THA in a familial case, intro-
duces an exonic splicing silencer sequence. Remarkably, all
the identiﬁed genes are coding proteins that orchestrates
proteasome, although they represent different functional
subunits (PSMA1, PSMA3—core particle and PSMD3 as
well as PSMD2—regulatory particles), depicted on Fig. 1.
The proteasome-related pathomechanism was additionally
supported by deletions of other proteasome associated
genes VPS13C (two patients) and RAD23B (one patient).
The development of the thyroid is indispensably linked
to the cardiovascular system due to juxtaposition of thyroid
bud and cardiogenic mesoderm. This fact is supported by
high occurrence of heart defects in children with congenital
hypothyroidism [22]. On the other hand, the dysfunction of
proteasomal-ubiquitin system is recently thoroughly
explored in the context of cardiac diseases [23, 24].
Heritability of thyroid dysgenesis accounts for only
about 2% of patients and for those cases, the contribution of
monogenic background is evidenced (TTFs). So far none of
the hypotheses proposed by the Abramowicz et al. (epige-
netic regulation, early somatic mutation, stochastic events)
referring to missing causes of thyroid developmental
anomalies including THA were evidenced [25]. Taking into
account high variability and a high frequency of de novo
occurring genomic events (particularly CNVs), the model of
Endocrine
autosomal dominant transmission proposed by the Macchia
et al. is still valid and feasible [5].
In conclusion, our results shed a new light on etiology of
THA, so far suspected to be linked only to mutations in the
genes directly involved in thyroid development, like TTFs.
We demonstrated, for the ﬁrst time, that genomic alterations
in proteasome-associated genes co-occur in patients pre-
senting this developmental anomaly.
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